{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} New Treatments for Relapsed Hematologic Malignancies After alloHCT

Activity Steps

1 Activity
2 Take Test 3Certificate

Purpose of Activity

To provide information on new therapeutic options for relapsed hematologic malignancies after allogenic hematopoietic cell (alloHCT) transplantation.

Learning Objectives

After completing this continuing education activity you will be able to:

  1. Identify new pharmacologic immunotherapy agents used in the treatment of relapsed hematologic malignancies after alloHCT transplantation.
  2. Examine potential adverse and serologic effects of immune checkpoint inhibitors and tyrosine kinase inhibitors.

Disclosures

The authors discuss the off label use of ipilimumab, sorafenib, and nivolumab in the treatment of patients who undergo allogeneic hematopoietic cell transplantation (alloHCT). This use is not yet approved by the FDA. The authors and planners have disclosed no potential conflicts of interest, financial or otherwise.

Price: $12.95

Credits:

  • ANCC 1.0 CH
  • DC - BON 1.0 CH
  • KY-BON 1.0 CH
  • GA - BON 1.0 CH

Lippincott Professional Development is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749. Lippincott Professional Development is also an approved provider of continuing nursing education by the District of Columbia Board of Nursing, Florida Board of Nursing, and Georgia Board of Nursing, #50-1223.







Planner
Test Code: OT1018
Published: Oct 2018
Expires: 12/31/2026
Sources: Oncology Times
Required Passing Score: 7/10 (70%)
Authors: Jacqueline S. Garcia, MD; Matthew S. Davids, MD, MMSc
Categories: Oncology
Specialties: Oncology
Topics: Immunotherapy , Monoclonal Antibodies (MAbs)